Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials
Immunology and inflammation biotech Alumis has demonstrated its lead drug candidate can hit a certain validated target to treat plaque ...
Tuesday, January 7, 2025
Tag: Alumis
Explore Israel's diverse narratives with The Israel Chronicle. Stay informed with unbiased reporting, insightful analysis, and comprehensive coverage of politics, culture, technology, and more. Discover the heartbeat of Israel through our trusted news platform.